Already in late-stage development (pivotal field study), Piedmont anticipates the first product to market to utilize its innovative technology may be an injectable for the treatment of upper respiratory infections in cats.
Improved compliance often means improved health
According to Doug Hepler, Ph.D., chief scientific officer at Piedmont, Today, veterinarians treating cases of upper respiratory infection will send home an oral antibiotic that requires pet owners to dose their animals once or twice a day for several days. Yet, according to pet owner compliance studies, unfortunately many of those doses won't be successfully administered to pets. Our ready-to-use subcutaneous injectable would place compliance directly within the control of veterinarians, thus eliminating the challenges that occur when pet owners—particularly those with cats--try to orally dose their pets.
Piedmont expects this to be the first of many injectables
We're seeing a trend among veterinarians towards a preference for injectable medications that can be administered in-clinic, says Roland Johnson, Piedmont CEO. For example, in several proprietary market research studies with veterinarians, nearly 100 percent indicated a desire to use injectables.
In addition to this first product in development, we have successfully formulated a second antibiotic into an injectable formulation which will target multiple diseases in dogs and cats, including urinary tract infections, Johnson adds. Our goal is to develop a portfolio of targeted antibiotics for in-clinic administration by veterinarians. All of our products are focused on dramatically improving convenience and compliance.